State shouldn’t define pharmaceutical ‘value’

Baker drug-pricing proposal is shortsighted

THERE’S A REASON that Americans get access to new cancer medicines two years earlier, on average, than patients in Europe: prices in the United States respond to medical needs and market demands, not public commissions using inflexible formulas. Unfortunately, Gov. Charlie Baker’s budget proposal fails to take this into consideration and could put cutting-edge treatments(...)

Read More »